Total cash and cash equivalents were $349.7 million as of March 31, 2025. Based on current plans and related estimates of anticipated cash inflows from DEXTENZA, the Company believes that its current cash balance is sufficient to support its planned expenses, debt service obligations, and capital expenditure requirements into 2028. This cash projection does not factor in the impact of potential clinical trial activities for AXPAXLI in NPDR and DME.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix Inc (OCUL) Q1 Earnings Cheat Sheet
- Ocular Therapeutix initiated with an Outperform at William Blair
- Buy Recommendation for Ocular Therapeutix: Axpaxli’s Potential to Revolutionize nAMD Treatment
- Ocular Therapeutix added to Analyst Current Favorites list at Raymond James
- Ocular Therapeutix initiated with an Outperform at RBC Capital